Press Release
Press Release
Exelixis-Discovered Compounds to Be Featured in 18 Presentations at 2016 ASCO Annual Meeting
An oral presentation will include pivotal overall survival data from the
METEOR study, the randomized phase 3 trial of cabozantinib versus
everolimus in patients with previously treated advanced renal cell
carcinoma (RCC). These data were submitted to the
“The overall survival data for cabozantinib from the METEOR trial
represent an important milestone in the treatment of advanced renal cell
carcinoma,” said
Cabozantinib will be the subject of nine presentations. The full schedule of cabozantinib presentations expected at the meeting is as follows (all times are in Central Daylight Time):
Oral Presentations:
[4506]
“Overall survival (OS) in METEOR, a randomized phase 3 trial of
cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with
advanced renal cell carcinoma (RCC).”
Dr.
Oral Abstract
Session: Genitourinary (Nonprostate) Cancer: 8 – 11 a.m.
Poster Presentations
[9068]
“MDM2 amplification (Amp) to mediate cabozantinib resistance in patients
(Pts) with advanced RET-rearranged lung cancers.”
Poster
Session: Lung Cancer—Non-Small Cell Metastatic
Poster presented
Note:
This is an Investigator-Sponsored Trial.
[3548] “Phase Ib study of cabozantinib plus panitumumab in KRAS
wild-type (WT) metastatic colorectal cancer (mCRC).”
Dr.
Poster
Session: Gastrointestinal (Colorectal) Cancer
Poster presented
Note:
This is an Investigator-Sponsored Trial.
[2565] “Population pharmacokinetic (PopPK) and exposure-response (ER)
modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma
(RCC) in the phase 3 METEOR study.”
Dr.
Poster Session: Developmental
Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Poster
presented
[1093] “Effect of cabozantinib treatment on circulating immune cell
populations in patients with metastatic triple-negative breast cancer
(TNBC).”
Dr.
Poster Session: Breast
Cancer—Triple-Negative/Cytotoxics/Local Therapy
Poster presented
Note: This
is an Investigator-Sponsored Trial.
[4534] “A phase II study of cabozantinib in patients (pts) with
relapsed or refractory metastatic urothelial carcinoma (mUC).”
Dr.
Poster Discussion Session: Genitourinary
(Nonprostate) Cancer
Poster presented
Note:
This is a National Cancer Institute Cancer Therapy Evaluation Program
(NCI-CTEP) study.
[4558] “Efficacy of cabozantinib (C) vs everolimus (E) in patients
(pts) with advanced renal cell carcinoma (RCC) and bone metastases
(mets) from the phase III METEOR study.”
Dr.
Poster Session:
Genitourinary (Nonprostate) Cancer
Poster presented,
[4557] “Outcomes based on prior VEGFR TKI and PD-1 checkpoint
inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib
(C) vs everolimus (E) in advanced renal cell carcinoma (RCC).”
Dr.
Poster Session: Genitourinary (Nonprostate) Cancer
Poster
Presented
[5586] “Phase II study of cabozantinib in recurrent/metastatic
endometrial cancer (EC): a study of the Princess Margaret,
Dr.
Poster
Session: Gynecologic Cancer
Poster Presented
Note: This is an NCI-CTEP study.
Investor/Analyst Briefing to Review Cabozantinib Data
XL888 Data to be Presented in a Poster
In addition,
investigational compound XL888 will be the subject of the following
poster presentation (in Central Daylight Time):
[9544] “Phase I study of vemurafenib and heat shock protein 90
(HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.”
Dr.
Poster Session: Melanoma/Skin Cancers
Poster presented
Note: This
is an Investigator-Sponsored Trial.
Cobimetinib to be Featured in Eight Presentations
Also at
the meeting, Exelixis’ collaborator Genentech, a member of the
Oral Presentation:
[3502]
“Clinical activity and safety of cobimetinib (cobi) and atezolizumab in
colorectal cancer (CRC).”
Dr.
Oral Abstract Session:
Gastrointestinal (Colorectal) Cancer
Oral presentation on
Poster Discussion:
[9510]
Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib
and vemurafenib in BRAF-mutant melanoma
Dr.
Poster
Session: Melanoma/Skin Cancers
Poster presentation from
Poster Presentations:
[9528]
“Clinical predictors of response for coBRIM, a phase 3 study of
cobimetinib (C) in combination with vemurafenib (V) in advanced
BRAF-mutated melanoma (MM).”
Dr.
Poster Session: Melanoma/Skin Cancers
[9530] “Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated
melanoma patients (pts) with poor and favorable prognosis in the coBRIM
phase 3 study.”
Dr. Grant A
Poster Session: Melanoma/Skin Cancers
[9533] “Adverse event (AE) incidence rates with cobimetinib (C) plus
vemurafenib (V) treatment: extended follow-up (f/u) of the phase 3
coBRIM study.”
Dr.
Poster Session: Melanoma/Skin Cancers
[9536] “Identifying prognostic subgroups for outcomes in
BRAFV600-mutated metastatic melanoma patients (pts) treated with
vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3,
BRIM-7 and coBRIM.”
Dr.
Poster Session: Melanoma/Skin Cancers
[1074] “Cobimetinib (C) + paclitaxel (P) as first-line treatment in
patients (pts) with advanced triple-negative breast cancer (TNBC):
updated results and biomarker data from the phase 2 COLET study.”
Dr.
Poster Session: Breast Cancer—Triple-Negative/Cytotoxics/Local
Therapy
[TPS1100] “COLET (NCT02322814): A multistage, phase 2 study
evaluating the safety and efficacy of cobimetinib (C) in combination
with paclitaxel (P) as first- line treatment for patients (pts) with
metastatic triple-negative breast cancer (TNBC).”
Dr.
Poster Session:
Breast Cancer —Triple-Negative/Cytotoxics/Local Therapy
About the METEOR Phase 3 Pivotal Trial
METEOR is an open-label, event-driven trial with the primary endpoint of
progression-free survival (PFS). The target enrollment for METEOR was
650 patients, and 658 patients were ultimately randomized. The trial was
conducted at approximately 200 sites in 26 countries, and enrollment was
weighted toward
Secondary endpoints for METEOR include overall survival (OS) and
objective response rate. The secondary endpoint of OS assumed a median
of 15 months for the everolimus arm and 20 months for the cabozantinib
arm. The study was designed to observe 408 deaths in the entire
intent-to-treat population of 650 planned patients, providing 80% power
to detect a HR of 0.75. An interim analysis of OS at the 2-sided 0.0019
level employing a Lan-DeMets O’Brien-Fleming alpha-spending function was
planned at the time of the primary analysis for PFS, if the trial met
the primary PFS endpoint. This analysis showed a strong trend in OS
favoring cabozantinib (HR=0.67, 95% CI 0.51-0.89, p=0.005), although the
p-value of 0.0019 to achieve statistical significance was not reached at
that time. Based upon these results and after consulting with the
About Advanced Renal Cell Carcinoma
The American Cancer Society’s 2016 statistics cite kidney cancer as among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S.1 Clear cell RCC is the most common type of kidney cancer in adults.2 If detected in its early stages, the five-year survival rate for RCC is high; for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 12 percent, with no identified cure for the disease.1 Approximately 17,000 patients in the U.S. and 37,000 globally require second-line or later treatment.3
The majority of clear cell RCC tumors have lower than normal levels of a
protein called
About Cabozantinib
Cabozantinib targets include MET, AXL and VEGF-1, -2 and -3 receptors. In preclinical models, cabozantinib has been shown to inhibit the activity of these receptors, which are associated with tumor angiogenesis, invasiveness, metastasis and drug resistance.
On
About the Cobimetinib and Vemurafenib Combination
Cobimetinib is a selective inhibitor that blocks the activity of MEK, a protein kinase that is part of a key pathway (the RAS-RAF-MEK-ERK pathway) that promotes cell division and survival. This pathway is frequently activated in human cancers including melanoma, where mutation of one of its components (BRAF) causes abnormal activation in about 50% of cases. Tumors with BRAF mutations may develop resistance and subsequently progress after treatment with a BRAF inhibitor. About 50% of patients with BRAF mutation positive melanoma experience a tumor response when treated with a BRAF inhibitor, however development of resistance and subsequent tumor progression limits treatment benefit. Clinical and preclinical analyses indicated that reactivation of the MEK-ERK pathway may underlie development of resistance to BRAF inhibitors in many progressing tumors, and that co-treatment with a BRAF and MEK inhibitor delays the emergence of resistance in the preclinical setting, providing the rationale for testing the combination of vemurafenib and cobimetinib in clinical trials. In addition to the combination with vemurafenib in melanoma, cobimetinib is also being investigated in combination with several investigational medicines, including an immunotherapy, in several tumor types, including non-small cell lung cancer, colorectal cancer, triple-negative breast cancer and melanoma.
About
Forward-Looking Statement Disclaimer
This press release contains forward-looking statements, including,
without limitation, statements related to: the continued focus of
Exelixis’ development efforts on the opportunities for cabozantinib in
advanced RCC, advanced HCC, and other disease settings; Exelixis’ intent
or understandings concerning the presentation of data at the upcoming
2016 Annual Meeting of the
References | |||||
1. |
American Cancer Society. Cancer Facts & Figures 2016. Atlanta: American Cancer Society; 2016. |
||||
2. |
Jonasch E., Gao J., Rathmell W.K., Renal cell carcinoma. BMJ. 2014; 349:g4797. |
||||
3. | Decision Resources Report: Renal Cell Carcinoma. October 2014 (internal data on file). | ||||
4. |
Harshman, L.C. and Choueiri, T.K., Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J. 2013; 19(4):316-23. |
||||
5. |
Rankin et al., Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 2014; 111(37):13373-8. |
||||
6. |
Zhou L, Liu X-D, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2015 Sep 14. doi:10.1038/onc.2015.343. [Epub ahead of print]. |
||||
7. |
Koochekpour et al.,The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 1999; 19(9):5902–5912. |
||||
8. |
Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994;54:4233-4237. |
||||
9. |
Nakagawa M, Emoto A, Hanada T, Nasu N, Nomura Y. Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma. Br J Urol. 1997;79:681-687. |
||||
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420006144/en/
Source:
Investors:
Exelixis, Inc.
Susan Hubbard,
650-837-8194
Investor Relations &
Corporate
Communications
shubbard@exelixis.com
or
Media:
Exelixis,
Inc.
Lindsay Treadway, 650-837-7522
Corporate
Communications
ltreadway@exelixis.com